Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Advanced Cancer 6Melanoma 3Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Malignancies Multiple 1Lymphoid Interstitial Pneumonia 1Lung Neoplasms 1Laryngeal Diseases 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Adenocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × linrodostat × Clear all
NCT03329846 2021-07-09

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Bristol-Myers Squibb

Phase 3 Completed
20 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡